Dravet Syndrome

Clever Leaves Holdings Inc. (NASDAQ: CLVR) (OTC: CLVRW), a prominent global medical cannabis company announced a strategic partnership with the renowned Dutch seed bank, Paradise Seeds to develop and register high-performance cannabis cultivars in Colombia. Through this partnership,...

Biopharma company developing next-generation mental health treatments Bright Minds Biosciences Inc. (NASDAQ: DRUG) has closed its overnight offering for gross proceeds of approximately $4 million. The company also announced it will start dosing patients in the trial of...

Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society 2021 Annual Meeting. STK-001 is under development to target the underlying cause of Dravet syndrome,...

Stoke Therapeutics Inc (NASDAQ: STOK) announced interim analysis data from Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome. The interim analysis is based on data from 21 patients who were treated in the single 10mg (n=5), 20mg (n=4), or 30mg (n=6...

By WeedMaps News' A.J. Herrington, provided exclusively to Benzinga Cannabis. As the legalization of marijuana continues to spread state by state, and the rising industry along with the culture of weed continue to evolve, it can be easy to forget that much of the legalization movement owes much...

Biotech stocks present an exciting investment opportunity, given the heady gains they can fetch if one places the right bet at the right time. The IPO Terms Stoke Therapeutics, Inc. this week proposes to offer 6.7 million shares at an estimated price range of $14-$16, according to an amended S-1...

Zogenix, Inc. (NASDAQ: ZGNX), which develops therapies for rare diseases, said Monday afternoon the FDA issued a refusal to file letter regarding its NDA for Fintepla, chemically fenfluramine hydrochloride, which is being evaluated for the treatment of seizures associated with Dravet syndrome. The...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced incremental positive news on its lead cannabinoid product candidate Epidiolex, sending the stock higher. What Happened GW Pharma announcedpositive results for a second, late-stage study that evaluated its Epidiolex oral solution for treatment...

Zogenix, Inc. (NASDAQ: ZGNX) peaked nearly 30 percent in Thursday's pre-market session after management released positive top-line results from its second pivotal Phase 3 study of ZX008 in Dravet Syndrome. The trial met primary and secondary endpoints and demonstrated statistical significance...

Medical journal The Lancet published an article Wednesday that could mold the future of cannabis-derived therapeutics. The piece in question featured results from GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) and Greenwich Biosciences’ Phase 3 study of Epidiolex — an oral cannabidiol...

Shares of Zogenix, Inc. (NASDAQ: ZGNX) traded higher by 200 percent early Friday morning after the company announced top-line results from a phase 3 clinical trial exploring its drug called ZX008 for the treatment of Dravet syndrome. Zogenix said that its trial met its primary objective of...